Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice

International Journal of Cancer

Volumn 126, Issue 10, 2010, Pages 2319-2329

  Pandruvada, Subramanya N M ^a   Yuvaraj, Sambandam ^a   Liu, Xiang ^b   Sundaram, Kumaran ^a   Shanmugarajan, Srinivasan ^a   Ries, William L ^c   Norris, James S ^b   London, Steven D ^c   Reddy, Sakamuri V ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bone invasion; Chemokine; MMP 9; Mouse model; Oral squamous cell carcinoma (OSCC); Osteoclast; RANK ligand

Indexed keywords

CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; GELATINASE B; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ANTIBODY; THROMBIN RECEPTOR ACTIVATING PEPTIDE; CXCL13 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE METASTASIS; CALVARIA; CANCER INVASION; CELL DIFFERENTIATION; CHEMOTAXIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MONOCYTE; MOUSE; MOUTH CARCINOMA; NONHUMAN; NUDE MOUSE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; STAINING; TUMOR CELL; ZYMOGRAPHY; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUTH TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHEMOKINE CXCL13; CHEMOTAXIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MOUTH NEOPLASMS; OSTEOLYSIS; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77951249158     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24920     Document Type: Article

References (40)

1. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002;24:165-180
2. Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 2008;87:14-32.
3. LoTempio MM, Veena MS, Steele HL, Ramamurthy B, Ramalingam TS, Cohen AN, Chakrabarti R, Srivatsan ES, Wang MB. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 2005;11:6994-7002. (Pubitemid 41428759)
4. ElOjeimy S, McKillop JC, El-Zawahry AM, Holman DH, Liu X, Schwartz DA, Day TA, Dong JY, Norris JS. FasL gene therapy: a new therapeutic modality for head and neck cancer. Cancer Gene Ther 2006;13:739-745 (Pubitemid 44100486)
5. Nelson K, Helmstaedter V, Lage H. The influence of tamoxifen on growth behavior and cell-cell adhesion in OSCC in vitro. Oral Oncol 2007;43:720-727 (Pubitemid 47061475)
6. Senkal CE, Ponnusamy S, Rossi MJ, Bialewski J, Sinha D, Jiang JC, Jazwinski SM, Hannun YA, Ogretmen B. Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 2007;6:712-722 (Pubitemid 46332472)
7. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-3545
8. Reddy SV. Regulatory mechanisms operative in osteoclasts. Crit Rev Eukaryot Gene Expr 2004;14:255-270
9. Nomura T, Shibahara T, Katakura A, Matsubara S, Takano N. Establishment of a murine model of bone invasion by oral squamous cell carcinoma. Oral Oncol 2007;43:257-262 (Pubitemid 46228010)
10. Deyama Y, Tei K, Yoshimura Y, Izumiyama Y, Takeyama S, Hatta M, Totsuka Y, Suzuki K. Oral squamous cell carcinomas stimulate osteoclast differentiation. Oncol Rep 2008;20:663-668
11. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127 (Pubitemid 30398626)
12. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. CXC chemokines in angiogenesis. J Leukoc Biol 2000;68:1-8.
13. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56
14. Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitza R, Schirlau K, Franken-Kunkel P, Poremba C, Snyderman C, Klotz LO, Ruzicka T, Bier H, et al. Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int J Cancer 2006;118:2147-2157
15. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cellattracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998;187:655-660 (Pubitemid 28093368)
16. Ziober AF, Patel KR, Alawi F, Gimotty P, Weber RS, Feldman MM, Chalian AA, Weinstein GS, Hunt J, Ziober BL. Identification of a gene signature for rapid screening of oral squamous cell carcinoma. Clin Cancer Res 2006;12:5960-5971 (Pubitemid 44703755)
17. Srinivasan S, Ito M, Kajiya H, Key LL, Jr, Johnson-Pais TL, Reddy SV. Functional characterization of human osteoclast inhibitory peptide-1 (OIP-1/hSca) gene promoter. Gene 2006;371:16-24.
18. Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R. Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med 2004;2:6. (Pubitemid 39130365)
19. Shanmugarajan S, Irie K, Musselwhite C, Key LL, Jr, Ries WL, Reddy SV. Transgenic mice with OIP-1/hSca overexpression targeted to the osteoclast lineage develop an osteopetrosis bone phenotype. J Pathol 2007;213:420-428 (Pubitemid 350206514)
20. Wright LM, Maloney W, Yu X, Kindle L, Collin-Osdoby P, Osdoby P. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone 2005;36:840-853 (Pubitemid 40616019)
21. Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res 2007;313:168-178 (Pubitemid 44958461)
22. Krieg C, Boyman O. The role of chemokines in cancer immune surveillance by the adaptive immune system. Semin Cancer Biol 2009;19:76-83.
23. Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, Yeudall WA. Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res 2006;66:4279-4284
24. Tada T, Shin M, Fukushima H, Okabe K, Ozeki S, Okamoto M, Jimi E. Oral squamous cell carcinoma cells modulate osteoclast function by RANKL-dependent and -independent mechanisms. Cancer Lett 2009;274:126-131
25. Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG. RANKL and. RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 2006;3:41-49
26. Sun L, Diamond ME, Ottaviano AJ, Joseph MJ, Ananthanarayan V, Munshi HG. Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. Mol Cancer Res 2008;6:10-20. (Pubitemid 351378162)
27. Grassi F, Piacentini A, Cristino S, Toneguzzi S, Cavallo C, Facchini A, Lisignoli G. Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12. Histochem Cell Biol 2003;120:391-400. (Pubitemid 38005358)
28. Christofakis EP, Miyazaki H, Rubink DS, Yeudall WA. Roles of CXCL8 in squamous cell carcinoma proliferation and migration. Oral Oncol 2008;44:920-926
29. Uchida D, Begum NM, Almofti A, Nakashiro K, Kawamata H, Tateishi Y, Hamakawa H, Yoshida H, Sato M. Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res 2003;290:289-302. (Pubitemid 37272173)
30. Wang J, Seethala RR, Zhang Q, Gooding W, van Waes C, Hasegawa H, Ferris RL. Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. J Natl Cancer Inst 2008;100:502-512
31. Lisignoli G, Cristino S, Toneguzzi S, Grassi F, Piacentini A, Cavallo C, Facchini A, Mariani E. IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation. Exp Gerontol 2004;39:659-665 (Pubitemid 38402094)
32. Lisignoli G, Toneguzzi S, Piacentini A, Cattini L, Lenti A, Tschon M, Cristino S, Grassi F, Facchini A. Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands. CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosaminidase release. J Cell Physiol 2003;194:71-79 (Pubitemid 35424229)
33. Lisignoli G, Toneguzzi S, Piacentini A, Cristino S, Grassi F, Cavallo C, Facchini A. CXCL12 (SDF-1) and CXCL13 (BCA-1) chemokines significantly induce proliferation and collagen type I expression in osteoblasts from osteoarthritis patients. J Cell Physiol 2006;206:78-85. (Pubitemid 41740719)
34. Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell JB, Baldwin AS, Jr, Van Waes C. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64:6511-6523 (Pubitemid 39297908)
35. Tada T, Jimi E, Okamoto M, Ozeki S, Okabe K. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. Int J Cancer 2005;116:253-262 (Pubitemid 40967262)
36. Tang CH, Chuang JY, Fong YC, Maa MC, Way TD, Hung CH. Bone-derived SDF-1 stimulates IL-6 release via CXCR4. ERK and NF-kappa B pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis 2008;29:1483-1492
37. St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, Shi W, Qi F, Wu B, Sinha U, Jordan R, Wolinsky L, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:929-935 (Pubitemid 39045599)
38. Watanabe H, Iwase M, Ohashi M, Nagumo M. Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. Oral Oncol 2002;38:670-679 (Pubitemid 34880105)
39. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, Shirai T, Matrisian LM, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7:485-496
40. Hohberger L, Wuertz BR, Xie H, Griffin T, Ondrey F. TNF-alpha drives matrix metalloproteinase-9 in squamous oral carcinogenesis. Laryngoscope 2008;118:1395-1399